VBI 002
Alternative Names: Anti CD47 anti ICAM1 bispecific antibody - Virtuoso Therapeutics; Anti CD47 anti ICAM1 bsAb - Virtuoso Therapeutics; Anti-CD47 X anti-ICAM-1 bsAb - Virtuoso Therapeutics; CD47 X ICAM-1 bsAb; VBI-002Latest Information Update: 29 May 2023
At a glance
- Originator Virtuoso Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Phagocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th annual meeting of the American Association for Cancer Research (AACR-2023)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 113th annual meeting of the American Association for Cancer Research (AACR-2022)
- 23 Mar 2022 Preclinical trials in Cancer in USA (Parenteral)